31 results
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Survival #EBM #Honc ... #Osimertinib #NSCLC ... #Survival #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Lung Cancer #EBM #Honc ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Plasmacytomas and Plasma-Cell Leukemia - Physical examination revealed multiple exophytic subcutaneous lesions involving the arms and
Wright–Giemsa stain) #Clinical ... #HONC #Derm #Plasmacytomas ... Leukemia #Smear #NEJM
Ecthyma Gangrenosum - A physical examination revealed a 2-cm hemorrhagic patch with an erythematous border (Panel
#Clinical #Derm ... #Honc #Ecthyma # ... #Neutropenic #NEJM
Diagnostic Algorithm for Non–Small-Cell Lung Cancer (NSCLC). The upper portion of the algorithm shows the morphologic
Non–Small-Cell Lung Cancer (NSCLC ... classification of NSCLC ... #Diagnosis #Honc ... #Algorithm #NSCLC ... #PDL1 #NEJM
Hemolysis in Hereditary Spherocytosis. Panel A shows the structure of a normal red cell and a
Pathophysiology #Honc ... #IM #Spherocytosis ... HereditarySpherocytosis #NEJM
Immunosuppressive Strategies for the Prevention or Treatment of Acute GVHD. Panel A shows several classic immunosuppressive
are in routine clinical ... been tested in clinical ... Pathophysiology #IM ... #Honc #Pharm #GVHD ... Immunosuppression #NEJM
A 48-year-old-man presented to the dermatology clinic with a whitish discoloration and hyperkeratosis of the first
the dermatology clinic ... #Clinical #IM #InfectiousDisease ... RapidProgression #NEJM
Clinical and Histopathological Findings in Chronic Graft-versus-Host Disease (GVHD). #Clinical #Honc #GVHD #GraftVersusHostDisease #NEJM
Clinical and Histopathological ... #Clinical #Honc ... GraftVersusHostDisease #NEJM